Product Description
Mechanisms of Action: Antithrombin Modulator,Thrombin Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | Bulgaria | Czech | Hungary | Italy | Korea | Lebanon | Malaysia | Mexico | Philippines | Poland | Portugal | Romania | Russia | Slovakia | Spain | Thailand | Tunisia | Turkey | Ukraine | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Akebia
Company Location: CAMBRIDGE MA 02142
Company CEO: John P. Butler
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Mexico
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Post Acute COVID-19 Syndrome|Thrombosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CMN-01-2021 | P3 |
Completed |
Post Acute COVID-19 Syndrome|Thrombosis |
2024-02-07 |
|
VEINS (VEnous INvestigation with Sulodexide) | P3 |
Completed |
Unknown |
2022-08-31 |